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Background: Renal dysfunction occurs commonly in patients awaiting orthotopic liver transplantation (OLT) for
end-stage liver disease. The use of simultaneous liver-kidney transplantation has increased in the MELD scoring era.
As patients may recover renal function after OLT, identifying factors predictive of renal recovery is a critical issue,
especially given the scarcity of available organs.
Methods: Employing the UNOS database, we sought to identify donor- and patient-related predictors of renal
recovery among 1720 patients with pre-OLT renal dysfunction and transplanted from 1989 to 2005. Recovery of
renal function post-OLT was defined as a composite endpoint of serum creatinine (SCr) ≤1.5 mg/dL at discharge
and survival ≥29 days. Pre-OLT renal dysfunction was defined as any of the following: SCr ≥2 mg/dL at any time
while awaiting OLT or need for renal replacement therapy (RRT) at the time of registration and/or OLT.
Results: Independent predictors of recovery of renal function post-OLT were absence of hepatic allograft
dysfunction, transplantation during MELD era, recipient female sex, decreased donor age, decreased recipient ALT
at time of OLT, decreased recipient body mass index at registration, use of anti-thymocyte globulin as induction
therapy, and longer wait time from registration. Contrary to popular belief, a requirement for RRT, even for
prolonged periods in excess of 8 weeks, was not an independent predictor of failure to recover renal function
post-OLT.
Conclusion: These data indicate that the duration of renal dysfunction, even among those requiring RRT, is a poor
way to discriminate reversible from irreversible renal dysfunction.Background
Renal dysfunction occurs commonly in patients with
end-stage liver disease (ESLD) awaiting orthotopic liver
transplantation (OLT) [1,2]. In the MELD (Model End-
Stage Liver Disease) scoring era, the use of simultaneous
liver-kidney transplantation (SLKT) has increased [3,4].
From a renal standpoint, considerable uncertainty re-
mains as to which patients will benefit from SLKT [4].
In many cases, pre-OLT renal dysfunction is ameliorated
by OLT [5,6]. Moreover, in patients with ESLD and renal
dysfunction, studies evaluating factors predictive of* Correspondence: jiglesias23@gmail.com
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reproduction in any medium, provided the orrecovery of renal function and/or or risk factors predict-
ive of non-recovery of renal function post-OLT have
yielded conflicting results [4,7].
Several factors complicate the decision whether pa-
tients should receive SLKT. Most important is the com-
plex interaction between the liver and kidney. The
cirrhotic milieu often leads to dramatic reductions in
renal perfusion, so that renal dysfunction in the setting
of cirrhosis may reflect prerenal factors rather than in-
trinsic renal damage. In the case of prerenal dysfunction,
OLT should lead to nearly full recovery of renal function.
While a renal biopsy can easily distinguish between
prerenal and intrinsic causes for renal insufficiency, the
coagulopathy associated with cirrhosis frequently pre-
cludes performing a biopsy [1,8-10]. These issues are
highlighted by the paucity of pathological data in nearly
all studies of the hepatorenal syndrome (HRS) [11,12].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identifying which patients with pre-OLT renal dysfunc-
tion will regain renal function post-OLT becomes an
even more critical issue. Previous studies have been
hampered by small population sizes, single center expe-
riences, and the retrospective nature of the data [8,10].
Employing the UNOS database, we sought to identify
donor- and patient-related predictors of renal recovery
and non-recovery in 1720 patients with pre-OLT renal
dysfunction and transplanted from 1989 to 2005. In this
cohort, the most important independent predictor of re-
covery of renal function post-OLT was an absence of
hepatic allograft dysfunction. Other predictors of renal
recovery were related to amelioration or reversal of the
cirrhotic milieu and/or improved renal perfusion, as
reflected by decreased severity of recipient liver disease
and a lack of use of calcineurin inhibitors, respectively.
An intriguing finding of our study is the potentially
beneficial effect of anti-thymocyte globulin induction,
which emerged as an independent predictor of renal re-
covery distinct from its calcineurin inhibitor-sparing ef-
fects. Finally, contrary to popular belief, our data suggest
that the requirement for renal replacement therapy, even
for prolonged periods in excess of 8 weeks, may not be




The study was undertaken in accordance with principles
of the Declaration of Helsinki and the standards of good
clinical practice. The study was approved by the Institu-
tional Review Board and Ethics Committee (IRB#06-
008) of Barnabas Health Community Medical Center.
Study population
The current study was designed as a retrospective co-
hort study. Data were obtained the United Network for
Organ Sharing (UNOS) for donors and OLT recipients
transplanted from January, 1989, through March, 2005,
the time of creation of our database. Recovery of renal
function following OLT was defined as a primary com-
posite end point of a serum creatinine (SCr) ≤1.5 mg/dL
at discharge and survival of ≥29 days. Patients included
in our analysis were those who possessed pre-OLT renal
dysfunction, defined as any of the following: (1) SCr
≥2 mg/dL at any time while awaiting OLT; (2) need for
renal replacement therapy (RRT) at the time of registra-
tion (dialysis at time of registration); (3) need for RRT at
time of OLT (dialysis at time of transplant); (4) need for
RRT at time of both registration and OLT (dialysis-de-
pendence). Patients were excluded from analysis if they
received multi-organ transplantation, were <17 years old
at the time of OLT, or received a living-related or living-unrelated OLT. In addition, patients were excluded if
their SCr was ≤1.5 mg/dL at the time of OLT and they
had received RRT neither at the time of registration nor
at the time of OLT. Data on the type of RRT, whether
intermittent or continuous, were not available.
Data collection
Data collected for OLT recipients included the following:
routine demographic variables (age, sex, race); wait time
from registration; registration and/or peri-transplant se-
verity of illness characteristics (body mass index [BMI]; in-
tensive care unit [ICU] admission; presence of ascites,
hepatic encephalopathy, or portal vein thrombosis [PVT];
need for mechanical ventilation, transjugular intrahepatic
portosystemic shunt [TIPS], or RRT); comorbidities (coron-
ary artery disease, diabetes mellitus, hypertension, periph-
eral arterial disease, cachexia); etiology of ESLD (fulminant
hepatic failure, hepatitis B, hepatitis C, non-alcoholic
chronic steatohepatitis [NASH], alcoholic cirrhosis, or
other); registration and/or peri-transplant physiologic
variables (clotting times, serum albumin, liver enzymes,
total bilirubin); MELD score; cold and warm ischemia
times; occurrence of allograft dysfunction; and im-
munosuppressive medications used for induction and/
or maintenance therapy (antithymocyte globulin,
OKT3, basiliximab, daclizumab, alemtuzumab, cyclospor-
ine, tacrilimus, sirolimus). Immunosuppressive usage was
reported for the immediate post-OLT period, before recov-
ery of renal function could occur. Renal variables collected
for OLT recipients included the requirement for RRT, SCr,
and estimated glomerular filtration rate (eGFR) at the times
of registration, OLT, and discharge. For patients receiving
RRT, several values of SCr were used, an unadjusted and
two adjusted values. The unadjusted SCr was the value en-
tered into the UNOS database. Given uncertainty whether
the entered SCr was obtained pre- or post-dialysis, analysis
was repeated using a single adjusted value for SCr of either
4.0 or 5.0 mg/dL. The former value is in accord with previ-
ous work by Bahirwani et al.[13] eGFR was determined
using the 4-variable equation of the Modification of Diet in
Renal Disease (MDRD) study group. Data collected for do-
nors included age, sex, race, BMI, terminal liver enzymes,
terminal total bilirubin, and whether the OLT derived from
a non-heart beating donor. Transplant related data include
type of induction therapy, initial immunosuppression, cold
ischemia time, warm ischemia time and liver allograft
function.
Data analysis
All statistical analyses unless otherwise indicated were
performed as a comparison for OLT recipients who recov-
ered renal function vs. those who did not. Summary statis-
tics were computed for the two cohorts, those with
recovery of renal function and those with non-recovery.
Figure 1 Recovery versus non-recovery of renal function
following orthotopic liver transplantation (OLT) in patients with
pre-OLT renal dysfunction grouped according to their need for
renal replacement therapy (RRT). Recovery of renal function
following OLT was defined as a composite end point of a serum
creatinine (SCr) ≤1.5 mg/dL at discharge and survival of ≥29 days.
Patients included in our analysis were those who possessed pre-OLT
renal dysfunction, defined as any of the following: (1) SCr ≥2 mg/dL
at any time while awaiting OLT, but not requiring RRT (SCr ≥2 mg/
dL, no dialysis); (2) need for RRT at registration, but not at OLT
(dialysis at registration only); (3) need for RRT at OLT, but not at
registration (dialysis at transplant only); (4) need for RRT at both
registration and OLT (dialysis-dependent).
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deviation and compared by the Student t test or the
Wilcoxon rank-sum test. For purposes of statistical analysis,
patients receiving RRT were assigned a SCr of 4 mg/dL.
Categorical variables were compared by Fisher's exact test
or chi-square analysis. Comparison of cohorts included
both univariate and multivariate analyses. Candidate vari-
ables for multivariate analysis included all variables found
to be significantly different by univariate analysis at p < 0.05.
To determine variables independently predictive of renal re-
covery, we performed logistic regression analysis with for-
ward variable selection. Stepwise selections for logistic
regression were based on the maximum likelihood ratio. For
continuous variables, the odds ratio (OR) represents the
relative amount by which the probability of observing recov-
ery of renal function increases or decreases if the independ-
ent variable is increased by exactly one unit. OR and their
95% confidence intervals (CI) were determined by exponen-
tiation of the regression coefficient or its upper and lower
95% CI, respectively.
Results
Univariate analyses of factors associated with non-
recovery of renal function post-OLT within the entire
cohort
To determine factors associated with recovery vs. non-
recovery of renal function following OLT, we analyzed
multiple routinely available demographic, clinical, and
laboratory variables obtained in OLT recipients with
pre-OLT renal dysfunction who were transplanted be-
tween 1989 and 2005.
A total of 1720 patients were evaluated. 863 (51%) pa-
tients recovered renal function, while 857 (49%) failed to re-
cover renal function. Notably, of those who recovered renal
function, 500 (58%) received RRT at some time prior to
OLT. Of these, 79 (16%) were on dialysis only at the time of
registration, 252 (50%) were on dialysis only at the time of
OLT, and 169 (34%) required RRT throughout their time
on the waiting list. A similar distribution was seen for those
who failed to recover renal function. 570 (67%) required
RRT at some time prior to OLT. 99 (17%) were on dialysis
only at the time of registration, 267 (47%) were on dialysis
only at the time of transplant, and 204 (36%) required RRT
throughout their time on the waiting list. Figure 1 depicts
the percentage of patients with recovery vs. non-recovery
of renal function according to their need for RRT at the
time of registration and/or OLT.
Using our entire cohort (n = 1720), we compared OLT re-
cipients with recovery vs. non-recovery of renal function by
univariate analysis for multiple characteristics, including
the following: recipient demographic variables and clinical
characteristics at both the time of registration and the time
of transplant (Table 1); recipient co-morbidities (Table 2);
etiology of ESLD (Table 3); common laboratory chemistries(Table 4); MELD score and allograft-related factors
(Table 5); immunosuppressive regimen (Table 6); and
donor demographic variables and clinical features
(Table 7).
The following recipient-related demographic and clinical
characteristics were associated with recovery of renal func-
tion post-OLT (Table 1): female sex (p < 0.05); lack of ICU
admission at the time of registration (p = 0.007); lack of
need for mechanical ventilation either at the time of regis-
tration (p = 0.00001) or at the time of OLT (p = 0.015); ab-
sence of PVT at the time of OLT (p = 0.025); lack of need
for RRT at the time of registration (p = 0.003), at the time
of OLT (p = 0.01), or at both times (p = 0.03); a longer time
on the waiting list (p = 0.00001); and a lower BMI either at
the time of registration (p = 0.019) or at the time of OLT
(p = 0.02).
OLT recipients who recovered renal function were more
likely to be receiving their first OLT (p = 0.007) and to have
no history of variceal bleeding (p = 0.032) (Table 2). The eti-
ology of their ESLD was less likely to be fulminant hepatic
failure (p = 0.039) or NASH (p = 0.04) (Table 3). They were
also less likely to have an elevated alanine transaminase
(ALT) (p = 0.007) (Table 4).
Recovery of renal function was associated with an ab-
sence of allograft dysfunction in the immediate post-OLT
period (p = 0.00001) and with transplantation during the
MELD era (p = 0.0001) (Table 5). Aspects of the immuno-
suppressive regimen also correlated with the likelihood of
renal recovery. Recovery of renal function was associated
Table 1 Demographic, listing, and peri-transplant characteristics in patients with pre-OLT renal dysfunction that are
associated with recovery of renal function post-OLT
Recovery of renal function (n=863) Non-recovery (n=857) p OR (95% CI)
Demographic characteristics
Age 50.3 ± 10.2 50.0 ± 10.5 0.3
Sex (male) 544 (63%) 581 (67%) 0.043 0.81 (0.66-0.98)
Race (Caucasian) 599 (70%) 620 (72%) 0.21 0.88 (0.70-1.07)
Listing characteristics
ICU admission 207 (24%) 255 (29%) 0.007 0.74 (0.60-0.92)
Mechanical ventilation 108 (13%) 172 (20%) 0.00001 0.57 (0.43-0.74)
Encephalopathy 510 (59%) 541 (60%) 0.35 1.08 (0.9-1.3)
Ascites 593 (72%) 598 (63%) 0.60 0.95 (0.75-1.16)
TIPS 57 (6.6%) 63 (7%) 0.63 0.92 (0.65-1.30)
PVT 17 (1.9%) 30 (3.5%) 0.052 0.55 (0.32-0.93)
Dialysis (at listing)* 248 (28%) 303 (32%) 0.003 0.63 (0.50-0.76)
BMI (kg/m2) 27.6 ± 5.5 28.4 ± 6.1 0.02
Peri-transplant characteristics
Wait time from listing (days) 178 ± 297 145 ± 266 0.00001
ICU admission 441 (51%) 417 (49%) 0.76 1.03 (0.85-1.20
Mechanical ventilation 206 (24%) 249 (29%) 0.015 0.76 (0.62-0.95)
Encephalopathy 343 40%) 344 (41%) 0.86 0.98 (0.81-1.20)
Ascites 580 (67%) 547 (64%) 0.14 1.20 (0.95-1.40)
TIPS 75 (8.6%) 79 (9.2%) 0.70 0.93 (0.67-1.30)
PVT 22 (2.5%) 39 (4.5%) 0.025 0.55 (0.32-0.99)
Dialysis (at transplant)* 421 (49%) 471 (55%) 0.01 0.70 (0.57-0.85)
Dialysis (at both listing and transplant) 169 (19%) 204 (23%) 0.03 0.78 (0.62-0.99)
BMI (kg/m2) 27.0 ± 6.4 28.0 ± 6.3 0.019
Abbreviations: BMI body mass index, CI confidence interval, ICU intensive care unit, OLT orthotopic liver transplant, OR odds ratio, PVT portal vein thrombosis, TIPS
transjugular intrahepatic porto-systemic shunt.
* The number of patients on dialysis at listing (n = 551) includes those on dialysis only at listing (n = 178) as well as those on dialysis at both listing and transplant
(n = 373). Similarly, the number of patients on dialysis at transplant (n = 892) includes those on dialysis only at listing (n = 519) as well as those on dialysis at both
listing and transplant (n = 373).
Iglesias et al. BMC Nephrology 2013, 14:147 Page 4 of 12
http://www.biomedcentral.com/1471-2369/14/147with use of antithymocyte globulin as an induction agent
(p = 0.014) and absence of use of tacrolimus (p = 0.029)
(Table 6).
With respect to donor-related factors (Table 7), recovery
of renal function occurred more frequently in recipientsTable 2 Co-morbidities in patients with pre-OLT renal dysfun
Recovery of renal function (n
Coronary artery disease 9 (1%)
Diabetes mellitus 204 (24%)
Hypertension 158 (18%)
Peripheral arterial disease 7 (0.8%)
Chronic obstructive pulmonary disease 4 (0.5%)
Re-transplantation 136 (16%)
Variceal bleeding 66 (7.7%)
Cachexia 218 (25%)
Abbreviations: CI confidence interval, OLT orthotopic liver transplantation, OR oddswhose allografts came from younger donors (p = 0.00001)
and donors with a smaller BMI (p = 0.007).
Finally, OLT recipients who recovered renal function
post-OLT had lower SCr and higher eGFR both at the time
of registration (p = 0.00001) and at the time of transplantction associated with recovery of renal function post-OLT
= 863) Non-recovery (n = 857) p OR (95% CI)
12 (1.3%) 0.66 0.68 (0.30-1.50)
235 (27%) 0.07 0.84 (0.70-1.00)
167 (19%) 0.53 0.90 (0.72-1.17)
9 (1%) 0.56 0.74 (0.27-2.00)
11 (1.3%) 0.07 0.38 (0.14-1.12)
178 (21%) 0.007 0.70 (0.56-0.90)
91 (11%) 0.032 0.70 (0.50-0.97)
228 (26%) 0.52 0.93 (0.75-1.15)
ratio.
Table 3 Etiology of end-stage liver disease in patients with pre-OLT renal dysfunction associated with recovery of
renal function post-OLT
Recovery of renal function (n = 863) Non-recovery (n = 857) p OR (95% CI)
Fulminant hepatic failure 89 (10%) 118 (14%) 0.039 0.73 (0.54-0.98)
Hepatitis B 41 (5.4%) 33 (4%) 0.27 1.29 (0.80-1.50)
Other 300 (36%) 318 (38%) 0.62 0.90 (0.77-1.10)
NASH 4 (0.4%) 12 (1.4%) 0.04 0.32 (0.1-1.0)
Hepatitis C 246 (28%) 223 (26%) 0.56 1.06 (0.97-1.30)
Alcoholic cirrhosis 183 (21%) 155 (18%) 0.10 1.20 (0.96-1.50)
Abbreviations: CI confidence interval, NASH non-alcoholic steatohepatitis, OLT orthotopic liver transplant, OR odds ratio.
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analyses included patients undergoing RRT, for whom
measurement of SCr bore an uncertain temporal relation-
ship to their dialysis. When parameters of renal function
were adjusted for patients receiving RRT by assigning themTable 4 Laboratory values in patients with pre-OLT renal dys
post-OLT
Recovery of renal fu
SCr at time of registration (mg/dL)* 2.4 ± 2.0
SCr at time of registration (mg/dL)
(adjusted for dialysis, SCr = 4 mg/dL)* 2.5 ± 1.6
SCr at time of registration (mg/dL)
(adjusted for dialysis, SCr = 5 mg/dL)* 2.8 ± 2.0
SCr at time of transplant 3.6 ± 2.0
SCr at time of transplant (mg/dL)
(adjusted for dialysis, SCr = 4 mg/dL) 3.84 ± 1.5
SCr at time of transplant (mg/dL)
(adjusted for dialysis, SCr = 5 mg/dL) 4.3 ± 1.6
eGFR at time of registration (cc/min) 57 ± 41
eGFR at time of registration (cc/min)
(adjusted for dialysis, SCr = 4 mg/dL) 51 ± 42
eGFR at time of registration (cc/min)
(adjusted for dialysis SCr = 5 mg/dL) 51 ± 43
eGFR at time of transplant (cc/min) 28 ± 21
eGFR at time of transplant (cc/min)
(adjusted for dialysis, SCr = 4 mg/dL) 20 ± 14
eGFR at time of transplant (cc/min)
(adjusted for dialysis, SCr = 5 mg) 19 ± 14
Serum ALT at time of transplant (units/L) 257 ± 888
INR at time of transplant 2.1 ± 1.5
Total bilirubin at time of transplant (mg/dL) 14.0 ± 14.4
Serum albumin at time of transplant (g/dL) 2.78 ± 0.76
* For patients receiving RRT, several values of SCr were used, an unadjusted and tw
database. Given uncertainty whether the entered SCr was obtained pre- or post-dia
or 5.0 mg/dL.
Abbreviations: ALT alanine transaminase, eGFR estimated glomerular filtration rate,
serum creatinine.a uniform SCr value of either 4.0 mg/dL or 5.0 mg/dL, con-
sistent with minimal renal function, then neither SCr or
eGFR retained its correlation with non-recovery of renal
function (Table 4). We return to this important issue later
(see Tables 8 and 9, and Discussion).function associated with recovery of renal function
nction (n = 863) Non-recovery (n = 857) p
2.9 ± 2.6 0.00001
2.4 ± 1.7 0.23
2.78 ± 2.0 0.30
4.0 ± 2.3 0.00001
3.8 ± 1.4 0.52
4.3 ± 1.6 0.80
50 ± 42 0.00001
53 ± 44 0.33
53 ± 46 0.33
22 ± 14 0.00001
21 ± 12 0.30
19 ± 12 0.49
489 ± 1379 0.007
2.2 ± 2.8 0.80
16.0 ± 16.0 0.38
2.82 ± 0.77 0.18
o adjusted values. The unadjusted SCr was the value entered into the UNOS
lysis, analysis was repeated using a single adjusted value for SCr of either 4.0
INR international normalized ratio, OLT orthotopic liver transplantation, SCr
Table 5 Allograft-associated characteristics of patients with pre-OLT renal dysfunction associated with recovery of
renal function post-OLT
Recovery of renal function (n = 863) Non-recovery (n = 857) p OR (95% CI)
Transplanted prior to MELD era 275 (31%) 344 (40%) 0.0001 0.69 (0.57-0.85)
Whole organ transplant 846 (98%) 846 (99%) 0.23 0.65 (0.31-1.21)
MELD score 33.7 ± 8.7 34 ± 9.2 0.40
Cold ischemia time (hrs) 7.6 ± 3.5 7.7 ± 3.6 0.98
Warm ischemia time (mins) 42 ± 20 41 ± 18 0.51
Allograft dysfunction 111 (13%) 303 (35%) 0.00001 0.27 (0.21-0.34)
Abbreviations: CI confidence interval, MELD model end-stage liver disease, OLT orthotopic liver transplantation, OR odds ratio.
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recovery of renal function post-OLT within the entire
cohort
We used forward stepwise logistic regression analysis to de-
termine which variables identified by univariate analyses
(Tables 1, 2, 3, 4, 5, 6 and 7) were independent predictors of
recovery of renal function (Table 8). Independent predictors
of recovery of renal function post-OLT, in descending order
of coefficient of determination, were absence of hepatic
allograft dysfunction, transplantation during the MELD era,
female sex of the recipient, decreased donor age, decreased
recipient ALT at OLT, decreased recipient BMI at registra-
tion, use of anti-thymocyte globulin as induction therapy,
and a longer wait time from registration.
Multivariate analysis of factors associated with non-
recovery of renal function post-OLT within subgroups
stratified according to the need for RRT
To determine whether the predictors of recovery of renal
function varied with the level of renal dysfunction prior to
OLT, as well as to address uncertainty in the measurement
of SCr among patients receiving RRT (see Table 4), we
performed a subgroup analysis of our cohort. We stratified
the cohort into the following 4 groups: (1) recipients with
SCr ≥2 mg/dL at any time while awaiting OLT, but not re-
quiring RRT (n = 650); (2) recipients requiring RRT at the
time of registration, but not at the time of transplant (dialy-
sis at registration only, n = 178); (3) recipients requiringTable 6 Immunosuppression in patients with pre-OLT renal d
post-OLT
Recovery of renal function (n =








Abbreviations: CI confidence interval, OLT orthotopic liver transplant, OR odds ratio.RRT at the time of transplant, but not at the time of regis-
tration (dialysis at transplant only, n = 519); (4) recipients
requiring RRT at both the time of registration and the time
of transplant (dialysis-dependence, n = 373).
For each subgroup, we performed a separate forward
stepwise logistic regression analysis using variables found to
be significant by univariate analysis (data not shown). The
results of the multivariate analysis for each subgroup are
summarized in Table 9. Notably, an absence of hepatic allo-
graft dysfunction was an independent predictor of recovery
of renal function in all 4 subgroups. Among patients with a
SCr ≥ 2 mg/dl at any time prior to OLT, but not requiring
RRT, an absence of allograft dysfunction was the only inde-
pendent predictor of recovery. Among patients requiring
RRT at registration only, the independent predictors of re-
covery of renal function, in descending order of coefficient
of determination, were absence of hepatic allograft dysfunc-
tion and a lower MELD score. Among patients requiring
RRT at transplant only, the independent predictors of recov-
ery of renal function, in descending order of coefficient of
determination, were an absence of allograft dysfunction,
transplantation during the MELD era, use of anti-thymocyte
globulin as induction therapy, lack of use of cyclosporine,
and lack of use of tacrolimus. The emergence of both anti-
thymocyte globulin induction therapy and lack of use of
cyclosporine or tacrolimus as independent predictors sug-
gests that the beneficial effect of anti-thymocyte globulin
induction extends beyond its sparing of calcineurinysfunction associated with recovery of renal function
863) Non-recovery (n = 857) p OR (95% CI)
16 (1.8%) 0.014 2.15 (1.2-4.0)
20 (2.3%) 0.90 0.99 (0.53-1.73)
32 (3.7%) 0.69 0.80 (0.55-1.50)
31 (3.6%) 0.27 0.74 (0.43-1.27)
2 (0.2%) 0.54 0.50 (0.44-5.30)
192 (22%) 0.75 0.96 (0.76-1.21)
479 (56%) 0.029 0.81 (0.67-0.97)
23 (2.7%) 0.74 0.87 (0.81-1.23)
Table 7 Donor characteristics in patients with pre-OLT renal dysfunction associated with recovery of renal function
post-OLT
Recovery of renal function (n = 863) Non-recovery (n = 857) p OR (95% CI)
Donor age 37 ± 17 39 ± 17 0.00001
Donor sex (male) 542 (62%) 536 (62)% 1.0 1.01 (0.87-1.19)
Donor race (Caucasian) 611 (71%) 603 (70%) 0.9 0.94 (0.97-1.12)
Donor BMI 25.6 ± 6.1 27.5 ± 13.0 0.007
Non-heart-beating donor 14 (1.6%) 14 (1.6%) 0.95 1.00 (0.47-1.80)
Donor ALT 53 ± 95 59 ± 158 0.12
Donor AST 70 ± 96 75 ± 176 0.35
Donor bilirubin (total) 1.0 ± 1.8 1.0 ± 1.7 0.79
Abbreviations: ALT alanine transaminase, AST asparatate transaminase, BMI body mass index, CI confidence interval, OLT orthotopic liver transplant, OR odds ratio.
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registration and transplant, the independent predictors of
recovery of renal function, in descending order of coeffi-
cient of determination, were an absence of allograft dys-
function, decreased donor age, decreased recipient total
bilirubin, and increased donor ALT. With regard to in-
creased donor ALT, the weakest of the predictors, it is note-
worthy that, despite statistical difference donor ALT was
within the normal range for patients with recovery vs. non-
recovery of renal function.
Analysis of the effect of time on waiting list on post-OLT
recovery of renal function
The duration of renal dysfunction is thought to impact
the likelihood of recovery of renal function post-OLT
[14]. Even when pre-OLT renal dysfunction is thought
to be solely prerenal, prolonged impairment of renal per-
fusion because of the cirrhotic milieu may lead to slow
ischemic dropout of glomeruli and tubules [12]. We
therefore analyzed the effect of time on the waiting list
among the 4 subgroups of OLT recipients with pre-OLT
renal dysfunction.
The mean duration of time on the waiting list did not
differ for OLT recipients with recovery vs. non-recoveryTable 8 Multivariate analysis of factors independently associa
patients with pre-OLT renal dysfunction
Regression coefficient S.E.
Allograft dysfunction −1.40 0.11
Transplanted before MELD era −0.363 0.12
Sex (male) −0.416 0.12
Donor age −0.008 0.003
Recipient ALT at time of transplant −0.0001 0.0001
Recipient BMI at time of listing −0.027 0.009
Anti-thymocyte globulin induction 0.79 0.34
Wait time from listing (days) 0.0001 0.152
Abbreviations: ALT alanine transaminase, BMI body mass index, CI confidence interv
OR odds ratio.
* The cumulative coefficient of determination for all variables combined is 0.093.of renal function for any of the 4 subgroups with pre-
OLT renal dysfunction (Table 10). Remarkably, this was
true even for those patients who received RRT both at
registration and at OLT (p = 0.91). A recent Consensus
Conference on SLKT identified 8 weeks as a threshold
duration of RRT beyond which the likelihood of renal
recovery was sufficiently low as to justify use of SLKT
[15]. We therefore repeated our analysis, restricting our
comparison to OLT recipients with wait times ≥8 weeks.
We again found no difference in the percentage of patients
with recovery vs. non-recovery of renal function for OLT
recipients whose wait times exceeded 8 weeks (Table 11).
Notably, this includes those recipients requiring RRT at
both registration and transplant (Table 11). Thus, among
82 dialysis-dependent patients with wait times of ≥8 weeks,
38 (46%) had recovery of renal function and 44 (54%) had
non-recovery (OR = 1.05, 95% CI = 0.65-1.75, p = 0.90). In
fact, recipients receiving RRT at the time of OLT and with a
wait time >8 weeks had an increased likelihood of recovery
vs. non-recovery of renal function (Table 11). Finally, we
used Fisher's exact test to compare the likelihood of renal
recovery in the subgroup of dialysis-dependent patients,
stratified according to whether their wait time was ≤8 weeks
vs. >8 weeks (Table 12). The percentage of patients havingted with recovery of renal function post-OLT in all
p OR (95% CI) Coefficient of determination*
0.00001 0.25 (0.18-0.33) 0.047
0.02 0.69 (0.55-0.87) 0.010
0.00001 0.66 (0.53-0.83) 0.009
0.014 0.992 (0.986-0.999) 0.007
0.026 1.0005 (1.000-1.001) 0.007
0.005 0.974 (0.95-0.99) 0.005
0.022 2.2 (1.12-4.30) 0.004
0.026 1.000 (1.000-1.001) 0.004
al, MELD model end-stage liver disease, OLT orthotopic liver transplantation,
Table 9 Multivariate analysis of factors independently associated with recovery of renal function post-OLT stratified
according to groups
Regression coefficient S.E. p OR (95% CI) Coefficient of variation
SCr ≥2 mg/dL, not requiring dialysis (n = 650)
Allograft dysfunction −1.388 0.090 0.0001 0.061 (0.163-0.383) 0.11
Dialysis at registration only
(n = 178)
Allograft dysfunction −1.86 0.55 0.00001 0.159 (0.054-0.990) 0.119
MELD score −0.019 0.021 0.016 0.95 (0.91-0.99) 0.058
Dialysis at transplant only
(n = 519)
Allograft dysfunction −1.42 0.26 0.00001 0.24 (0.14-0.40) 0.084
Transplanted before MELD −0.83 0.21 0.00001 0.43 (0.289-0.670) 0.033
Anti-thymocyte globulin induction 1.76 0.70 0.010 4.80 (1.23-19.10) 0.019
Cyclosporine −0.77 0.27 0.030 0.46 (0.27-0.78) 0.011
Tacrolimus −0.5 0.23 0.029 0.40 (0.40-0.95) 0.011
Dialysis-dependence
(n = 373)
Allograft dysfunction −1.752 0.358 0.00001 0.173 (0.086-0.350) 0.139
Donor age −0.019 0.008 0.020 0.98 (0.96-1.0) 0.044
Recipient bilirubin (total) −0.025 0.009 0.004 0.97 (0.96-0.99) 0.040
Donor ALT 0.008 0.003 0.020 1.008 (1.001-1.015) 0.028
Abbreviations: ALT alanine transaminase, BMI body mass index, CI confidence interval, MELD model end-stage liver disease, OLT orthotopic liver transplantation,
OR odds ratio, SCr serum creatinine.
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time (45% for ≤8 weeks vs. 46% for >8 weeks, p = 0.90).
Discussion
Using the UNOS database, we performed a retrospective
analysis to determine factors predictive of recovery of renal
function among OLT recipients with pre-OLT renal dys-
function. We defined recovery of renal function as a com-
posite end point of SCr ≤1.5 mg/dL at discharge and
survival ≥29 days. We report several major findings.
First, as in previous studies, recovery of renal function
occurred in ~50% of patients with pre-OLT renal dys-
function. This percentage was consistent across all sever-
ities of pre-OLT renal function, including patients who
required RRT at registration and/or OLT (cf. Figure 1).
In accord with our data, Marik et al. reported that 58%
of 28 patients with type I HRS recovered renal functionTable 10 Wait time in days from listing until OLT in patients
grouped by categories of pre-OLT renal dysfunction
Recovery
SCr ≥2 mg/dL, not requiring dialysis (n = 650) 363 ± 233
Dialysis at time of listing (n = 178) 125 ± 224
Dialysis at time of transplant (n = 519) 251 ± 182
Dialysis-dependence (n = 373) 79 ± 170post OLT [6]. Shusterman et al. described post-OLT re-
covery of renal function in 13 of 17 patients (77%) with
pre-OLT HRS (77%) and in 8 of 12 (67%) with pre-OLT
acute kidney injury (AKI) [16]. Davis et al. reported that
only 1.5% of patients with severe pre-OLT renal dysfunc-
tion (eGFR <30 ml/min) required kidney transplantation
within 1 year after OLT, suggesting that recovery of renal
function had occurred in a large percentage of these pa-
tients [4]. Notably, in the MELD era, for patients requir-
ing RRT at the time of registration, ~15% of those listed
for OLT alone and ~6.5% of those listed for SKLT no
longer required RRT at the time of OLT [4]. Northrup
et al., evaluating 1041 patients with pre-OLT renal dys-
function requiring RRT from 2002 to 2007, observed
spontaneous renal recovery in 68% of patients [5]. Fi-
nally, in a cohort of 155 patients who received SKLT,
Levitsky et al. observed that up to 40% of patientswith recovery vs. non-recovery of renal function post-OLT
of renal function Non-recovery p
287 ± 217 0.51
84 ± 210 0.21
261 ± 146 0.16
76 ± 180 0.91
Table 11 Percent of patients with wait time greater than 8 weeks stratified according to recovery vs. non-recovery of
renal function post-OLT grouped by categories of pre-OLT renal dysfunction
Recovery of renal function Non-recovery p OR (95% CI)
SCr ≥2 mg/dL, not requiring dialysis
(n = 391)
219 (56%) 172 (44%) 0.9 1.01 (0.84-1.20)
Dialysis at time of listing
(n = 51)
28 (55%) 23 (45%) 0.73 1.90 (0.94-3.50)
Dialysis at time of transplant
(n = 211)
114 (54%) 97 (46%) 0.035 1.45 (1.026-2.07)
Dialysis-dependence
(n = 82)
38 (46%) 44 (54%) 0.9 1.05 (0.65-1.75)
Iglesias et al. BMC Nephrology 2013, 14:147 Page 9 of 12
http://www.biomedcentral.com/1471-2369/14/147recovered function of their native kidneys, with post-
OLT GFR of their native kidneys being in the range of
GFR 30 to 40 mL/min, as assessed by nuclear scanning
[17]. Thus, across a broad range of studies, recovery of
renal function is a not uncommon occurrence among
OLT recipients with pre-OLT renal dysfunction, even
those requiring RRT.
Second, the single factor most predictive of renal re-
covery was an absence of hepatic allograft dysfunction.
This was true across all levels of pre-OLT renal dysfunc-
tion. Thus, an absence of hepatic allograft dysfunction
emerged as the strongest independent predictor of renal
recovery not only in our entire cohort of 1720 patients
(Table 8), but also in each of our four subgroups of renal
dysfunction (Table 9): (1) SCr ≥2 mg/dL at any time
pre-OLT, but not requiring RRT (n = 650); (2) RRT at
registration, but not at OLT (n = 178); (3) RRT at OLT,
but not at registration (n = 519); (4) RRT at both regis-
tration and OLT (n = 373). Remarkably, in the first sub-
group, an absence of allograft dysfunction was the only
independent predictor of renal recovery, whereas in the
second subgroup it was the stronger of only two inde-
pendent predictors.
We speculate that hepatic allograft dysfunction may im-
pede recovery of renal function through multiple mecha-
nisms. Possible contributory factors include persistence of
the cirrhotic milieu, surgical complications, need for re-
operation, and adverse systemic factors associated with allo-
graft dysfunction, such as vascular thrombosis, reperfusion
syndrome, hemorrhage, inflammation, or infection [18,19].
Such factors may not only prevent recovery of renal func-
tion post-OLT, but also lead to superimposed AKI. Indeed,Table 12 Recovery of renal function among dialysis-dependen
greater than or less than 8 weeks
Recovery of renal function (n = 169)
Wait time >8 weeks 38 (46%)
(n = 82)
Wait time ≤8 weeks 131 (45%)
(n = 291)
Abbreviations: CI confidence interval, OLT orthotopic liver transplantation, OR oddsseveral studies have observed a strong association between
hepatic allograft dysfunction and post-OLT renal dysfunc-
tion and/or need for RRT [19,20].
Other predictors of post-OLT recovery of renal func-
tion, identified within our entire cohort or within one or
more of our subgroups, may also relate indirectly to allo-
graft dysfunction. For example, our study concurs with
others in showing a worse outcome with the use of older
donors [5,21,22] (Tables 8 and 9). While the mechanism
for the detrimental effect of older donor age on renal re-
covery is not fully understood, a slower onset of hepatic
allograft function may be contributory [23,24]. There is
also evidence that the livers from older donors are at
greater risk for ischemia-reperfusion injury [25-27], al-
though there is no universal agreement on this point
[28]. Transplantation within the MELD era was also as-
sociated with a greater likelihood of post-OLT renal re-
covery. We observed this in the entire cohort (Table 8)
and in the subgroup requiring RRT at OLT only (Table 9).
Advantages within the MELD era include improved surgical
technique and peri-transplant management, both leading to
improved allograft function [18,29-33]. We cannot, how-
ever, exclude other beneficial aspects of the MELD era, such
as minimization of nephrotoxic immunosuppression and
earlier transplantation of patients with pre-OLT renal dys-
function, especially those requiring RRT [34-36].
Third, most of the remaining predictors of renal recovery
relate either to the severity of the recipient's liver disease or
to the choice of immunosuppressive regimen post-OLT.
Thus, within our entire cohort (Table 8), or within one or
more subgroups (Table 9), independent predictors of renal
recovery included a lower recipient MELD score, at recipients of OLT stratified according to wait time
Non-recovery (n = 204) p OR (95% CI)
44 (54%) 0.90 1.05 (0.65-1.75)
160 (55%) 0.87 1.025 (0.80-1.30)
ratio, SCr serum creatinine.
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ALT. A decreased recipient BMI was also an independent
predictor of renal recovery, and may reflect the absence of
ascites. Alternatively, an increased recipient BMI may
reflect obesity rather than ascites. In this case, renal re-
covery may be impaired because of obesity-associated
inflammatory responses or an increased risk for a small-
for-size allograft with resultant allograft dysfunction
and renal hypoperfusion [37,38].
With respect to the immunosuppressive regimen, lack
of use of cyclosporine or tacrolimus emerged as an inde-
pendent predictor of renal recovery. This is most likely
because of renal hypoperfusion and other potentially
nephrotoxic effects associated with use of calcineurin in-
hibitors [39]. Patients not treated with a calcineurin in-
hibitor tended to receive sirolimus. Thus, of 434 patients
who did not receive a calcineurin inhibitor, 417 (96%) re-
ceived sirolimus; correspondingly, of 1286 patients who
received a calcineurin inhibitor, only 27 (2%) received
sirolimus (p=0.057).
One of the more intriguing findings of our study is
the possibly beneficial effect of anti-thymocyte globulin
induction, which emerged as independent predictor of
renal recovery within our entire cohort (Table 8) and
among patients requiring RRT at the time of OLT
(Table 9). The most obvious benefit of anti-thymocyte
globulin induction lies in the fact that its use permits
minimization of the dose of calcineurin inhibitors [40].
However, there may be additional more direct benefits,
as suggested by the fact that failure to use calcineurin
inhibitors and administration of anti-thymocyte globu-
lin induction were retained as independent predictors
in our multivariate analysis. In addition to the promin-
ent T cell-depleting effects of anti-thymocyte globulin,
this polyclonal antibody binds to and neutralizes mul-
tiple antigens present not only on T cells but also on
neutrophils and other inflammatory cells, particularly
adhesion molecules and chemokine receptors, both of
which are involved in the recruitment of inflammatory
cells to areas of ischemia-reperfusion injury [40]. Fi-
nally, anti-thymocyte globulin may have increased the
likelihood of renal recovery by minimizing the occur-
rence of acute allograft rejection. Several facts argue
against this. The incidence of acute allograft rejection
was very low overall, and not different in patients who
received anti-thymocyte globulin versus those who did
not anti- (0% vs. 0.8%, p=1.00). Moreover, on univariate
analysis, the absence of an acute rejection episode
failed to predict renal recovery (p = 0.77).
Finally, in contrast to some studies [4,13-15], our data
suggest that among patients with pre-OLT renal dysfunc-
tion a shorter duration of time on the transplant list is not
an independent predictor of post-OLT renal recovery. In-
deed, for the entire cohort, a longer, and not a shorter, waittime predicted renal recovery (Table 8). Notably, when we
restricted our analysis to patients who required RRT at
both registration and OLT, and were therefore presumably
dialysis-dependent, we observed the following. Neither the
mean wait time (Table 10) nor the percentage of patients
with wait times >8 weeks (Table 11) was statistically differ-
ent for recipients recovering renal function vs. those lacking
renal recovery (Table 10). Moreover, the percentage of
dialysis-dependent patients with post-OLT recovery of renal
function was virtually the same in recipients with wait times
greater than 8 weeks vs. less than 8 weeks (46% vs. 45%).
These data highlight the importance of the cirrhotic milieu
in compromising renal function, and suggest that reversible
prerenal factors may predominate for prolonged periods of
times, even lengths of time typically thought to be indica-
tive of chronic irreversible renal damage.
With respect to the length of time on RRT, several con-
siderations may bear on the discrepancy between our re-
sults and those of previous studies. Patients with longer
wait times may be healthier and able to survive longer until
receiving an OLT. In addition, since the need for RRT was
recorded only at registration and transplantation, we cannot
be sure that dialysis-dependent patients required RRT for
the entire intervening period. This point requires further
study. In support of our findings, Machicao et al. reported a
negative association between an elevated SCr pre-OLT and
the development of progressive renal dysfunction post-OLT,
suggesting recovery of renal function in these patients post-
OLT [36]. In contrast, Bahirwani et al. found that the dur-
ation of renal dysfunction and the presence of pre-OLT
diabetes mellitus were inversely correlated with post-
OLT improvement and preservation of renal function
[13]. Others studies have also suggested that a longer
duration of pre-OLT renal dysfunction is a risk factor
for non-recovery of renal function [6,14]. It is pertinent
to note that some studies in which native kidney func-
tion was evaluated following OLT have observed recov-
ery of native kidney function after protracted periods of
time, between 75 and 365 days [6,17,41].
Our study has a number of strengths. The most import-
ant is our use of the UNOS database, containing prospect-
ive data from over 100 centers over a period of >20 years.
An additional strength is the large size of our cohort, which
is greater than that of previous studies [13,14]. In addition,
we used a rigorous definition of recovery of renal function,
requiring a composite endpoint of survival ≥29 days plus a
SCr ≤1.5 mg/dL at discharge. Finally, we evaluated predic-
tors of renal recovery not only in the entire cohort, but also
in several subgroups of patients with varying degrees of
pre-OLT renal dysfunction.
We note several limitations to our study. First, the retro-
spective nature of our study limited our ability to acquire
data, for example, the requirement for intra-operative trans-
fusion or vasopressors. Second, the UNOS database
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were unable to determine the exact duration of pre-OLT
renal dysfunction. Third, we lacked information on the eti-
ology of pre-OLT renal dysfunction. The distinction be-
tween pre-renal and renal causes is especially critical in
patients with liver failure. Post-OLT recovery of renal func-
tion is more likely for patients whose renal dysfunction is
attributable to reversible pre-renal factors from the cirrhotic
milieu, and less likely for patients whose renal dysfunction
results from intrinsic factors attributable to chronic irre-
versible damage. Finally, we used the MDRD formula to de-
termine eGFR. While estimates of renal function in
cirrhotic patients based on SCr are known to overestimate
the true GFR, it is important to emphasize that our analysis
was limited to the correlation between renal recovery and
changes, rather than absolute levels, of eGFR.
Conclusion
In summary, our study suggests that the most important
independent predictor of renal recovery in OLT recipi-
ents is the absence of hepatic allograft dysfunction. The
immunosuppressive regimen appears also to be import-
ant, with avoidance of calcineurin inhibitors and use of
anti-thymocyte globulin induction both associated with
post-OLT recovery of renal function. Importantly, the
mechanism of action of anti-thymocyte globulin induction
appears to be distinct from that of calcineurin inhibitor
sparing. Our study further suggests that reversible prerenal
factors attributable to the cirrhotic milieu play a major etio-
logic role in approximately 50% of patients with re-OLT
renal dysfunction. Our data also indicate that the duration
of renal dysfunction, even among those requiring RRT, is a
poor way to discriminate reversible from irreversible renal
dysfunction. Given the scarcity of organs available for
SLKT, a clear need exists for additional studies, incorporat-
ing renal biopsy data. These studies will help not only to
determine which patients should receive SLKT rather than
OLT alone, but also to identify peritransplant regimens that
enhance the likelihood of post-OLT renal recovery.
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